Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern

 
• By Kevin Grogan

The Swiss major is very happy indeed with the growth trajectory of Cosentyx and Entresto and pleased with how its migraine drug Aimovig has started. However the revelation of manufacturing problems with its CAR-T therapy Kymriah marred Novartis' second-quarter results.

Horses
Cosentyx and Entresto lead sales charge at Novartis • Source: Shutterstock

More from Earnings

More from Business